Ocugen, inc.OCGN.US Overview
OCGN Overall Performance
OCGN AI Analysis & Strategy
OCGN Recent Performance
5.81%
Ocugen, inc.
0.81%
Avg of Sector
-1.14%
S&P500
OCGN PowerScanner
OCGN Key Information
OCGN Valuation Metrics
OCGN Earnings Table
OCGN Profile
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.